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Abstract: p53 protein isoform expression has been found to correlate with prognosis and chemother-
apy response in acute myeloid leukemia (AML). We aimed to investigate how p53 protein isoforms
are modulated during epigenetic differentiation therapy in AML, and if p53 isoform expression
could be a potential biomarker for predicting a response to this treatment. p53 full-length (FL),
p53β and p53γ protein isoforms were analyzed by 1D and 2D gel immunoblots in AML cell lines,
primary AML cells from untreated patients and AML cells from patients before and after treatment
with valproic acid (VPA), all-trans retinoic acid (ATRA) and theophylline. Furthermore, global gene
expression profiling analysis was performed on samples from the clinical protocol. Correlation
analyses were performed between p53 protein isoform expression and in vitro VPA sensitivity and
FAB (French–American–British) class in primary AML cells. The results show downregulation of
p53β/γ and upregulation of p53FL in AML cell lines treated with VPA, and in some of the patients
treated with differentiation therapy. p53FL positively correlated with in vitro VPA sensitivity and the
FAB class of AML, while p53β/γ isoforms negatively correlated with the same. Our results indicate
that p53 protein isoforms are modulated by and may predict sensitivity to differentiation therapy
in AML.
Keywords: p53 protein isoforms; acute myeloid leukemia; differentiation therapy; French–American–
British (FAB) classification; valproic acid; all-trans retinoic acid
1. Introduction
p53 isoforms have over the last decades emerged as promising potential biomarkers
in cancer diagnosis and in therapy response prediction [1–4]. The different p53 isoforms
are involved in a complex interplay, where they influence the activity of one another and
regulate a variety of cellular processes [5–8]. p53 isoforms have been found to predict
prognosis in cancer types like esophageal squamous cell carcinoma, prostate cancer, ovar-
ian cancer, renal cell carcinoma, breast cancer and acute myeloid leukemia (AML) [9–16].
Although TP53 mutations are rare in AML, wild type p53 function is often inactivated
through various mechanisms [17]. High levels of the p53 wild type protein have been
associated with adverse karyotype and poor prognosis in therapy-related AML [18]. In-
duction chemotherapy in AML leads to a shift in p53 protein isoform expression, with
increased p53 full length (FL) and decreased p53β/γ protein isoforms, accompanied by
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elevated expression of p53 target genes [19]. At diagnosis, AML patients with low levels
of p53FL and high levels of p53β/γ protein isoforms seem to have a better prognosis and
response to chemotherapy than patients with already high levels of p53FL and low levels
of p53β/γ [16].
Differentiation therapy has been considered a promising approach for the treatment of
AML for several decades, inspired by the tremendous effect of all-trans retinoic acid (ATRA)
in the treatment of acute promyelocytic leukemia, as well as the extensive biological effects
in acute myeloid leukemia cells in general [20]. However, despite the encouraging effects
of several differentiation inducing agents like valproic acid (VPA) and ATRA alone and
in combination in cellular models, clinical efficacy in non-acute promyelocytic leukemia
remains moderate [21–23]. Improved knowledge about the molecular biology and therapy-
induced signaling is therefore necessary to increase the efficiency of differentiation therapy.
The main aim of this work was to investigate if p53 protein isoform expression could
be a potential independent biomarker for predicting a response to differentiation therapy in
AML. We used 2D gel immunoblots of p53FL and p53β/γ protein isoforms and an in-house-
developed pixel-by-pixel correlation method, and showed that in vitro VPA sensitivity
of primary AML cells positively correlated with the expression of p53FL and negatively
correlated with the expression of p53β/γ protein isoforms.
2. Materials and Methods
2.1. Cell Lines and AML Patient Material
The human AML cell lines MOLM-13 and MV4-11 were purchased from ATCC
(American Type Culture Collection, Manassas, VA, USA) and cultured according to the
manufacturer’s procedure. For patient material, all studies were performed in accordance
with the Helsinki declaration and approved by the Regional Ethics Committee (REC West-
ern Norway numbers 2017/305, 2015/1410, 215.03 and 231.06). Samples were collected
after informed consent, and peripheral blood mononuclear cells (PBMC) were isolated
and stored frozen in liquid nitrogen as previously described [24]. Only patients with at
least 80% of the leukocytes being AML cells were included in the study. The percentage of
AML blasts among leukemia PBMC exceeded 95%. The clinical studies were registered in
public databases (ClinicalTrials.gov no. NCT00175812 and EudraCT no. 2004-001663-22;
ClinicalTrials.gov no. NCT00995332 and EudraCT no. 2007–2007–001995-36.). Clinical
parameters including French–American–British (FAB) classification, cell surface mark-
ers, karyotype, resistance, survival and FLT3/NPM1 mutational status were routinely
analyzed and collected. RNA extraction and p53 mutational analysis was performed as
previously described [25].
2.2. Compounds
Valproic acid (Orfiril, Desitin Arzneimittel GmbH, Hamburg, Germany) (100 mg/mL
in solution) was stored at −80 ◦C for cell culture work.
2.3. Western Blotting
1D and 2D gel electrophoresis and immunoblotting were performed as previously
described [16,26]. The following primary antibodies were used; p53 (Bp53-12), Mdm2
(SMP-14) (Santa Cruz Biotechnology, CA, USA), Mdm2 (2A10), Mdm2 (IF2) (Calbiochem,
San Diego, CA, USA), p21 (SX118) (BD Biosciences, San Jose, CA, USA), actin (AC-15)
(Abcam plc, Cambridge, UK) and p53 (DO-12) (Courtesy of Dr. Jean-Christophe Bourdon,
Department of Surgery and Molecular Oncology, University of Dundee, Scotland, UK),
previously validated in [5,16]. The p53 (Bp53-12) and p53 (DO-12) antibodies are both
mouse monoclonal antibodies. The Bp53-12 antibody binds to the N-terminus of p53, and
detects p53 FL, p53β and p53γ protein isoforms. The p53 (DO-12) antibody binds to an
epitope common to all p53 isoforms, and detects all p53 protein isoforms. p53 (Bp53-12)
was used for 2D gel immunoblots, as this antibody gives a clear pattern for p53FL and
p53β/γ isoform expression with minimal background signals. For cell lines, both p53
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(Bp53-12) and p53 (DO-12) were used for 1D gel immunoblots, while only p53 (DO-12)
was used for the 1D gel immunoblots for patient samples due to limited material (and
in order to detect all p53 isoforms for later studies). The following secondary antibodies
were used: secondary horseradish peroxidase conjugated mouse and rabbit antibodies
(Jackson ImmunoResearch, West Grove, PA, USA). Regions in 1D gel immunoblots were
quantified using ImageJ software version 1.53a (Wayne Rasband, National Institutes of
Health, Bethesda, MD, USA).
2.4. Flow Cytometry
Histone acetylation, proliferation, differentiation and apoptosis markers in primary
AML cells were analyzed by flow cytometry as previously described [27]. Samples were
analyzed using a FACS Calibur flow cytometer (Becton Dickinson Immunocytometry
Systems, San Jose, CA, USA) with an Argon laser (488 nm) and a red diode laser (635 nm).
Data were analyzed using Cell Quest Lysis II software (Becton Dickinson).
2.5. Cell Proliferation Assay
An evaluation of proliferation in primary AML cells after drug treatment was per-
formed using 3H-thymidine (Amersham International, Amersham, UK) incorporation
assay as previously described [26]. Cells were cultured at 2 × 105 cells/mL and treated
with VPA (0 and 0.5 mM) for 48 h. 3H-thymidine (5 mCi in 100 mL NaCl) was added (20 µL
3H-thymidine to 200 µL cell suspension) 8 h before harvesting and analysis of the cells
using a Packard Microplate Scintillation and Luminescence counter (PerkinElmer Life And
Analytical Sciences, Inc., Waltham, MA, USA). Triplicates were analyzed for each sample.
2.6. Gene Expression Profiling
Global gene expression profiling of primary AML cells before and during in vivo
treatment was performed as previously described [28]. All microarray experiments were
performed using the Illumina iScan Reader (Illumina, San Diego, CA, USA), which is
based upon fluorescence detection of biotin-labelled cRNA. Three hundred ng of total RNA
from each sample was reversely transcribed, amplified and Biotin-16-UTP-labelled using
the Illumina TotalPrep RNA Amplification Kit (Applied Biosystems/Ambion, Carlsbad,
CA, USA). The amount and quality of the Biotin-labelled cRNA was controlled both by
the NanoDrop spectrophotometer (Thermo Scientific, Wilmington, DE, USA) and Agilent
2100 Bioanalyzer (Agilent Technologies, Santa Clara, CA, USA). Biotin-labelled cRNA
(750 ng) was hybridized to the HumanHT-12 V4 Expression BeadChip according to the
manufacturer’s instructions. The HumanHT-12 V4 BeadChip targets 47,231 probes that are
mainly derived from genes in the NCBI RefSeq database (Release 38). Data from the array
scanning on Illumina iScan Reader were investigated in GenomeStudio and J-Express 2012
for quality control measures. All arrays within each experiment were quantile-normalized
to be comparable before being compiled into an expression profile data matrix. Identified
genes were classified by use of the PANTHER version 11 (protein annotation through
evolutionary relationship) classification system, and the STRING database version 10.0 for
network analyses. We have analyzed selected samples from a previous publication, where
raw data are stored at Gene Expression Omnibus (accession number GSE106096). Patient
numbers 1–6 (day 1/8) in our study correspond to patient numbers 31-1/31-3, 17-1/17-3,
42-1/42-3, 14-1/14-3, 23-1/23-3 and 26-1/26-3 in the stored raw data.
2.7. Correlation Method and Statistical Analysis
Correlation analysis was performed as previously described [16,29]. 2D gel images
were aligned and normalized before Spearman rank-order correlations were performed
using self-developed software. Pixel-by-pixel correlations between gel intensities and the
biological variable (here, VPA response or FAB class) created a new image, showing areas
in the gel image that correlated to the biological variable (the red color indicates positive
correlation, while the blue color indicates negative correlation).
Cells 2021, 10, 833 4 of 14
In addition to this main method for correlation analysis, we also performed a more
traditional correlation analysis where we quantified regions of interest in 2D gel images
using ImageJ software. Separate values for p53FL, p53β/γ and the ratio of p53FL:p53β/γ
were obtained (signal in region of interest minus background signal in similar region),
and Spearman correlations or partial correlations were performed using SPSS software
(IBM SPSS Statistics version 25.0, IBM Corp., Armonk, NY, USA). Spearman correlations
were performed on original values, while partial correlations were performed on log2-
transformed values for p53FL, p53β/γ and the ratio of p53FL:p53β/γ. For all statistical
analysis, p < 0.05 was considered significant. Graphs and calculations were obtained using
GraphPad Prism® version 6.0 (GraphPad Software, La Jolla, CA, USA) and SPSS software.
3. Results
3.1. p53 Protein Isoform Expression Correlates with In Vitro Sensitivity to Valproic Acid in
Primary AML Cells
We previously developed a bioinformatic method and software to determine Spear-
man correlations between p53 protein isoform expression in 2D gel immunoblots and
biological parameters [16,29]. In order to investigate if p53 protein isoform expression
could provide independent information regarding sensitivity to differentiation therapy
in AML patients, we performed a correlation analysis between p53 protein isoform ex-
pression and in vitro sensitivity to VPA in primary AML cells (PBMC with >95% AML
blasts) (n = 21) (see Table 1 for patient characteristics). Primary AML cells were treated
with 0.5 mM VPA for 48 h, followed by a determination of proliferation (3H-thymidine
incorporation), while an analysis of p53 isoforms was performed in untreated samples. The
samples were analyzed by p53 2D gel immunoblotting (detecting p53 FL, p53β and p53γ
isoforms), images were aligned and normalized and correlation analysis was performed as
previously described [16]. Examples of p53 protein isoform expression in patient samples
with high and low sensitivity to VPA in vitro are shown in Figure 1A. The correlation
analysis demonstrated a significant positive correlation between VPA sensitivity and the
expression of p53 FL (correlation coefficient = 0.80, t-value = 5.96, p-value < 0.005), and
a significant inverse correlation between VPA sensitivity and the expression of p53β/γ
isoforms (correlation coefficient = −0.61, t-value = 5.50, p-value < 0.005) (Figure 1B) (See
Supplementary Table S1 and Supplementary Figure S1-1 values for VPA sensitivity and
2D gel images). This indicates that the more sensitive patient samples would express high
levels of p53 FL and low levels of p53β/γ isoforms.
Table 1. Acute myeloid leukemia (AML) patient characteristics (in vitro valproic acid (VPA) re-
sponse correlation).
Age and Gender Fab Classification
Median age (years) 63 M0/1 6
Range age (years) 29/82 M2 4
Female 11 M3 1
Male 12 M4/5 10
Total 21
Previous Malignancies Cytogenetics
MDS 2 Adverse 3
CML, recidiv 1 Favorable 2
PVR 1 Intermediate 11
MDS, AML relapse 1 Unknown 5
Cancer ovarii 1
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Table 1. Cont.
Mutations CD-markers
NPM1 mutations CD13 neg 1
Mut 4 pos 16
WT 6 CD14 neg 15
n.d. 11 pos 2
FLT3 mutations CD15 neg 12
ITD 4 pos 5
WT 14 CD33 neg 0
n.d. 3 pos 17
TP53 mutations CD34 neg 6
Mut (del) 2 pos 11
WT 17 n.d. 3
n.d. 2
Disease res. Survival (months)
Yes 7 Median survival 4






Abbreviations: CD, Cluster of differentiation; Del, Deletion; Disease res, Resistant disease; FAB, French-American-
British classification of acute myeloid leukemia M0-M6; FLT3, FMS-like tyrosine kinase 3; ITD, Internal tandem
duplication; MDS, Myelodysplastic syndrome; Nd, Not determined; NPM1, Nucleophosmin 1; PVR, Polycythemia
vera; WT, Wild-type. In vitro valproic acid response was determined by 3H-thymidine proliferation assay, and
given as % change compared to untreated control.
As a supplement to this self-developed correlation analysis, we also quantified regions
of interest in 2D gel images using ImageJ software. Spearman correlations in SPSS demon-
strated significant positive correlations between the VPA response and p53FL (r = 0.465,
p = 0.039) and between the VPA response and the ratio of p53FL:p53β/γ (r = 0.673, p = 0.001).
No significant correlation was found between the VPA response and p53β/γ (r = −0.071,
p = 0.767). Pearson correlations using log2-transformed values for p53FL, p53β/γ and
the ratio of p53FL:p53β/γ demonstrated significant correlation only between the VPA
response and the ratio (r = 0.610, p = 0.004). Furthermore, partial correlations between the
VPA response and the ratio demonstrated significant positive correlations when controlling
for p53FL (r = 0.513, p = 0.025), and when controlling for p53β/γ (r = 0.574, p = 0.010) (See
Supplementary Figure S1-2).
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Figure 1. Correlation analysis between p53 protein isoform expression and in vitro sensitivity to valproic acid in primary 
AML cells. AML samples from 21 patients were analyzed by 2D gel electrophoresis with separation of proteins according 
to molecular weight (kDa) and isoelectrical point (pI), and Western blotting using an antibody against p53 (Bp53-12) for 
detection of p53FL, p53β and p53γ protein isoforms. In vitro VPA sensitivity was determined by treatment of cells with 
VPA (0 and 0.5 mM) for 48 h followed by an assessment of proliferation by 3H-thymidine incorporation assay. Prolifera-
tion values were calculated as % VPA response (decrease in proliferation) compared to untreated control. Examples of 
p53 protein isoform expression in p53 2D gel images from patient samples with low and high sensitivity to VPA are 
shown in (A). Correlation analysis between p53 protein isoform expression and VPA sensitivity was performed. Regions 
with significant correlation values are indicated (the red color indicates positive correlation, the blue color indicates 
negative correlation): β/γ region: correlation coefficient = −0.61, t-value = 5.50, p-value < 0.005, FL: correlation coefficient = 
0.80, t-value = 5.96, p-value < 0.005 (B). 
3.2. p53 Protein Isoform Expression Correlates with the Differentiation Stage of AML Blasts 
We performed a correlation analysis between p53 protein isoform expression and 
French–American–British (FAB) classification (morphology and differentiation stage) in 
29 AML patient samples previously not analyzed (see Table 2 for patient characteristics). 
Examples of p53 protein isoform expression in patient samples from patients with FAB 
M1 (low level of differentiation) versus patients with FAB M4/5 (high level of differenti-
ation) are shown in Figure 2. The correlation analysis was carried out as described above, 
and demonstrated a significant inverse correlation between FAB classification and the 
Figure 1. Correlation analysis between p53 protein isoform expression and in vitro sensitivity to valproic acid in primary
AML cells. AML samples from 21 p tients were analyzed by 2D gel electrophoresis with separation of proteins according
to molecular weight (kDa) and isoelectrical poi t (pI), and Western blotting using an antibody against p53 (Bp53-12) for
detection of p53FL, p53β and p53γ protein isoforms. In vitro VPA sensitivity was determined by treatment of cells with
VPA (0 and 0.5 mM) for 48 h followed by an assessment of proliferation by 3H-thymidine incorporation assay. Proliferation
values were calculated as % VPA response (d crease in prolife ation) comp red to untreated control. Examples of p53
protein isoform expression in p53 2D gel images from patient samples with low and high sensitivity to VPA are shown
in (A). Correlation analysis between p53 protein isoform expression and VPA sensitivity was performed. Regions with
significant correlation values are indicated (the red color indicates positive correlation, the blue color indicates negative
correlation): β/γ region: correlation coefficient = −0.61, t-value = 5.50, p-value < 0.005, FL: correlation coefficient = 0.80,
t-value = 5.96, p-value < 0.005 (B).
3.2. p53 Protein Isoform Expression Correlates with the Differentiation Stage of AML Blasts
We perform d a corr lation analy is b tween p53 protein isoform expression and
French–American–Br tish (FAB) classification (morphology and differentiation stage) in
29 AML patient samples previously not analyzed (see Table 2 for patient characteristics).
Examples of p53 protein isoform expression in patient samples from patients with FAB M1
(low level of differentiation) versus patients with FAB M4/5 (high level of differentiation)
are shown in Figure 2. The correlation analysis was carried out as described above, and
demonstrated a significant inverse correlation between FAB classification and the p53β/γ
region (correlation coefficient = −0.52, t-value = 4.51, p-value < 0.005), indicating that AML
patient samples of a less differentiated phenotype would express higher levels of p53β/γ
isoforms than the more differentiated phenotype (higher FAB classification). Furthermore,
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significant positive correlations were observed for the more acidic (lower pI) regions of
p53 FL (FL1: correlation coefficient = 0.39, t-value = 3.14, p-value < 0.005, FL2: correlation
coefficient = 0.33, t-value = 2.59, p-value < 0.02), and a significant negative correlation
was observed for the less acidic region of p53 FL (FL3: correlation coefficient = −0.32,
t-value = 2.50, p-value < 0.02), indicating that patient samples with higher differentiation
stage would express higher levels of more acidified (putatively phosphorylated and ac-
tivated) forms of p53 FL (more detailed information is in Supplementary Table S1 and
Supplementary Figure S2).
Table 2. AML patient characteristics (French–American–British (FAB) correlation).
Age and Gender Fab Classification
Median age (years) 64 M0/1 11
Range age (years) 34-82 M2 5
Female 13 M3 0
Male 16 M4/5 12
Total 29 M6 1
Previous Malignancies Cytogenetics
MDS 6 Adverse 5
CML, recidiv 1 Favorable 1
AML, recidiv 1 Intermediate 11
PVR 1 Unknown 12
MDS, AML relapse 1
Mutations CD-markers
NPM1 mutations CD13 neg 3
Mut 3 pos 22
WT 14 CD14 neg 18
n.d. 12 pos 6
FLT3 mutations CD15 neg 10
ITD 10 pos 11
WT 15 CD33 neg 6
n.d. 4 pos 19
TP53 mutations CD34 neg 8
Mut (del) 2 pos 13
WT 22 n.d. 4
n.d. 5
Disease res. Survival (months)
Yes 5 Median survival 5
No 7 Survival range 0–72
n.d. 17
Abbreviations: CD, Cluster of differentiation; Del, Deletion; Disease res, Resistant disease; FAB, French-American-
British classification of acute myeloid leukemia M0-M6; FLT3, FMS-like tyrosine kinase 3; ITD, Internal tandem
duplication; MDS, Myelodysplastic syndrome; Nd, Not determined; NPM1, Nucleophosmin 1; PVR, Polycythemia
vera; WT, Wild-type.
3.3. p53 Protein Isoforms Are Modulated by Valproic Acid in AML Cell Lines
Considering the observed correlation between p53 protein isoform expression and the
differentiation stage of AML blasts described above, we investigated the modulation of
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p53 isoform expression in differentiation therapy of AML. The AML cell lines MOLM-13
(AML FAB M5a) and MV4-11 (AML FAB M5) were treated with VPA (0, 0.5, 1 and 2 mM)
for 48 and 72 h, followed by 2D gel immunoblot analysis with an antibody against p53
(Bp53-12; detects p53 FL, p53β and p53γ) (Figure 3A), or 1D gel immunoblot analysis
using antibodies against p53 (DO-12; detects all p53 isoforms), p53 (Bp53-12), p21 and
actin (Figure 3B). p53 2D gel immunoblots showed the same pattern as for the correlation
analysis, with downregulation of p53β/γ isoforms in more differentiated cells (those
treated with VPA), while 1D gel immunoblots also demonstrated upregulation of p53 FL
concomitant with the downregulation of p53β/γ isoforms after VPA treatment in both cell
lines, similar to the expression pattern of patient samples with a high level of differentiation
from Figure 2 (for details, see Supplementary Figure S3-1 and 3-2).
Additional correlation analyses were performed with the quantification of regions
of interest in 2D gel images using ImageJ software and Spearman correlation analysis in
SPSS. The results demonstrated a significant negative correlation between the FAB class
and p53β/γ (r = −0.4294, p = 0.023), and no significant correlations between the FAB class
and p53FL (r = 0.057, p = 0.775) or between the FAB class and the ratio of p53FL:p53β/γ
(r = 0.2719, p = 0.162).




Figure 2. Correlation analysis between p53 protein isoform expression and morphological differentiation stage (French–
American–British classification) of AML blasts. 29 primary AML samples with defined FAB classification were analyzed 
by 2D gel electrophoresis and Western blotting using an antibody against p53 (Bp53-12) for the detection of p53 full 
length (FL), p53β and p53γ protein isoforms. Examples of p53 protein isoform expression in p53 2D gel images from pa-
tient samples of low and high FAB class (M1 versus M4/5) are shown. A correlation analysis between p53 protein isoform 
expression and FAB classification (patient samples were assigned values from 0-6 based on FAB class) of the AML blasts 
was performed. Regions with significant correlation values are indicated (the red color indicates positive correlation, the 
blue color indicates negative correlation): β/γ region: correlation coefficient = −0.52, t-value = 4.51, p-value < 0.005), FL1: 
correlation coefficient = 0.39, t-value = 3.14, p-value < 0.005, FL2: correlation coefficient = 0.33, t-value = 2.59, p-value < 
0.02), FL3: correlation coefficient = −0.32, t-value = 2.50, p-value < 0.02. 
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Figure 2. Correlation analysis between p53 protein isoform expression and morphological differentiation stage (French–
American–British classification) of AML blasts. 29 primary AML samples with defined FAB classification were analyzed by
2D gel electrophoresis and Western blotting using an antibody against p53 (Bp53-12) for the detection of p53 full length (FL),
p53β and p53γ protein isoforms. Examples of p53 protein isoform expression in p53 2D gel images from patient samples of
low and high FAB class (M1 versus M4/5) are shown. A correlation analysis between p53 protein isoform expression and
FAB classification (patient sampl s were assigned values f om 0-6 based on FAB class) of the AML blasts was performed.
Regions with significant correlation values are indicated (the red color indicates positive correlation, the blue color indicates
negative correlation): β/γ region: correlation coefficient = −0.52, t-value = 4.51, p-value < 0.005), FL1: correlation coefficient
= 0.39, t-value = 3.14, p-value < 0.005, FL2: correlation coefficient = 0.33, t-value = 2.59, p-value < 0.02), FL3: correlation
coefficient = −0.32, t-value = 2.50, p-value < 0.02.
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3.4. In Vivo Modulation of p53 Protein Isoforms during Differentiation Therapy of AML
We investigated p53 isoform expression in patient material from a clinical protocol
where patients were treated with oral ATRA 22.5 mg/m2 twice daily for the first 14 days,
and VPA together with theophylline from day 3 until disease progression, as previously
described [27]. Samples were collected before treatment (day 1), after 2 days of treatment
with ATRA alone (day 3) and after 5 additional days of treatment with the triple combi-
nation (day 8). 1D gel immunoblots of p53 isoform expression (detected by p53 DO-12)
from the 6 different patients at different time points during treatment (day 1, 3 and 8)
demonstrated a modulation of p53 isoform expression also in vivo during differentiation
therapy (Figure 4).
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demonstrated a modulation of p53 isoform expression also in vivo during differentiation 
therapy (Figure 4). 
Two of the patients responded with downregulation of p53β/γ isoforms on day 8, 
similar to AML cell lines treated with VPA in vitro, one of them also accompanied by a 
significant increase in p21. As patient material may differ in levels of actin and other 
Figure 3. Valproic acid-induced modulation of p53 protein isoforms in AML cell lines. (A) The AML
cell line MOLM-13 (AML FAB M5a) was treated with VPA (0, 0.5, 1.0 and 2.0 mM) for 48 and 72 h,
and analyzed by 2D gel electrophoresis and Western blotting for the detection of p53 full-length (FL),
p53β and p53γ protein isoforms (Bp53-12). (B) AML cell lines MOLM-13 and MV4-11 (AML FAB M5)
were treated with VPA (0, 0.5, and 1.0 mM) for 48 a d 72 h and analyzed by 1D gel electrophoresi
and Western blotting using antibodies against p53 (DO-12), p53 (Bp53-12) and p21. Actin was used
as a loading control. Regions in Western blots (p53 DO-12) were quantified, and ratios of p53 FL:
p53β/γ were calculated and given as fold induction of control.
Two of the patients respon ed with downregulation of p53β/γ isoforms on day 8,
similar to AML cell lines treated with VPA in vitro, one of them also accompanied by a
significant increase in p21. As patient material may differ in levels of actin and other
commonly used loading controls, the ratio between p53 FL and p53β/γ isoform expression
was calculated, demonstrating an increased p53 FL: p53β/γ ratio in some of the samples
during treatment. Clinical parameters of the patient material and response to treatment are
described below, and were determined previously [27] (see Supplementary Table S2 and
Supplementary Figure S4 for more detailed characteristics).
A gene expression profiling analysis was performed for the same patients before and
after therapy (Supplementary Figures S5 and S6). Distinct gene expression profiles were
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identified after treatment. Functional network analysis revealed two protein networks of
special interest; (i) the network related to proliferating cell nuclear antigen (PCNA), and
(ii) protein interactions related to phosphatase and tensin homolog (PTEN). Both protein
networks are connected to the p53 pathway at various levels of regulation [30–34].
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Figure 4. In vivo modulation of p53 protein isoforms during differentiation therapy in AML. Samples
were collected from AML patients undergoing combination therapy of valproic acid (VPA), all-trans
retinoic acid (ATRA) and theophylline before treatment (day 1), after treatment with ATRA (day 3) and
after treatment with the triple combination (day 8). Samples were analyzed by 1D gel electrophoresis
and Western blotting with antibodies against p53 (DO-12), p21 and actin. Regions in Western blots
were quantified and ratios of p53 FL: p53β/γ were calculated and given as fold induction of control
(day 1). Clinical parameters including TP53, FLT3 and NPM1 status, FAB classification, CD34, CD15
and response to treatment, including peripheral blood counts and circulating AML blasts are shown
below. Histone acetylation, proliferation, differentiation and apoptosis markers are analyzed by flow
cytometry. Results are based on median fluorescence intensity (MFI), except from CD markers and
cell cycle markers, where results are based on % positive cells. Response to treatment is marked
grey for not done, black for no change, red for increase and blue for decrease. Abbreviations:
ac, acetylation; Bax, Bcl-2-like protein 4; Bcl-2, B-cell lymphoma; CD, cluster of differentiation;
FAB, French–American–British; FL, full-length; FLT3, FMS-like tyrosine kinase 3; GATA, globin
transcription factor; H3, Histone H3; H4, Histone H4; IkBa, nuclear factor of kappa light polypeptide
gene enhancer in B-cells inhibitor, alpha; ITD, Internal tandem duplication; MDS, myelodysplastic
syndrome; ND, not done; NFkB, nuclear factor kappa-light-chain-enhancer of activated B cells; Wt,
Wild type.
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4. Discussion
The observed correlation between p53 protein isoform expression and in vitro VPA
sensitivity in primary AML cells indicates that patients with high levels of p53FL and
low levels of p53β/γ would be more sensitive to treatment with VPA. Several reports
suggest that high expression of p53FL, low expression of p53β/γ isoforms and a high
ratio of p53FL relative to p53β/γ isoforms are associated with an adverse prognosis in
leukemia patients [16,18]. The fact that patients with this adverse p53 expression pattern
were the most sensitive to VPA treatment suggests that this therapy may be beneficial in
particular for patients with poor prognosis. This is promising for further development
of differentiation therapy, a therapy approach suggested to provide clinical benefit in
high-risk AML patients [21–23,27]. However, the results need to be validated in larger
studies, ideally with correlative analysis of p53 isoform expression with response to in vivo
differentiation therapy.
p53 protein isoform expression also correlated with FAB classification (differentiation
stage) of AML, indicating that patient AML blasts with a low level of differentiation
would express high levels of p53β/γ isoforms compared to patients with a high level
of differentiation. This is consistent with findings of Hofstetter and colleagues, who
reported an association between expression of p53β with poorly differentiated ovarian
cancers [11]. In this study, p53β expression also correlated with poor recurrence-free and
overall survival. Conversely, AML patients with elevated expression levels of p53β/γ
protein isoforms demonstrated improved responses to chemotherapy and increased overall
survival [16]. Furthermore, breast cancer patients expressing p53γ together with mutated
p53 had a prognosis as good as those expressing wild type p53 [15], and high levels of
p53β were associated with disease-free survival in breast cancer [14]. These studies and our
results suggest that the p53 isoforms are differentially expressed in cancer cells of various
differentiation stages and may predict prognosis and therapy response; however, this may
differ according to cancer type and type of therapy.
The advantage of the self-developed pixel-by-pixel correlation method is that it is
sensitive and gives a detailed correlation for specific parts of the p53 protein isoform
profile. This method showed a stronger correlation between the VPA response and p53FL
compared to the VPA response and p53β/γ (correlation coefficients 0.80 vs. −0.61). The
alternative method used for correlation analysis (quantification with ImageJ and Spearman
or partial correlations) was not as sensitive. However, we could also calculate correlations
between the VPA response and the ratio of p53FL: p53β/γ using this method. The ratio was
a stronger predictor of the VPA response compared to p53FL (correlation coefficients 0.610
vs. 0.384), and remained significant also after controlling for p53FL or p53β/γ. However,
p53FL did influence the relationship between the VPA response and the ratio of p53FL:
p53β/γ to some degree.
In AML cell lines expressing wild type p53, there was a marked downregulation of
p53β/γ isoforms after VPA treatment, as well as an upregulation of p53FL. Interestingly, a
modulation of p53 protein isoforms was also detected in vivo during differentiation therapy.
A noticeable downregulation of p53β/γ isoforms was observed in some of the patients,
while the increase in p53FL was (as expected) not as evident as for in vivo chemother-
apy [16]. p53FL and p53β/γ isoforms are shown to participate in the regulation of can-
cer development and in cellular processes like differentiation and apoptosis [35,36], and
p53β/γ isoforms have been found to enhance both p53FL functions and p53-independent
chemosensitivity [5,37,38]. In AML cells with already activated p53 (cells treated with
chemotherapy or cells with a high level of differentiation), it is possible that differentia-
tion therapy could be sufficient to induce differentiation or apoptosis in a p53-dependent
manner. Combination therapy focusing on modulating p53 isoform expression to a more
favorable profile prior to differentiation therapy could therefore be feasible [39].
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5. Conclusions
Altogether, our results demonstrate that p53 isoform expression is modulated by
differentiation therapy in AML, both in vitro and in vivo, and that p53 isoform expression
could affect sensitivity to differentiation-inducing agents. We anticipate that p53 protein
isoform expression analysis may add independent information on predicting therapy
response. Future studies should include a correlation analysis of p53 isoform expression
with response to in vivo differentiation therapy, as well as explore the potential of p53
isoform-targeted therapy in aggressive blood cancers like AML.
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